Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals was planning to go public, but the IPO was withdrawn on Jun 14, 2024.

IPO Price

$11.87

Shares Offered

17,000,000

Deal Size

$201.79M

Telix Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is January - December.

Millions AUD. Fiscal year is Jan - Dec.

Year	2023	2022
Revenue	502.55	160.1
Revenue Growth (YoY)	213.90%	-
Cost of Revenue	188.16	65.17
Gross Profit	314.39	94.93
Selling, General & Admin	133.85	87.1
Research & Development	128.84	81.01
Other Operating Expenses	35.85	18.75
Operating Expenses	298.55	186.86
Operating Income	15.84	-91.93
Interest Expense / Income	12.75	6.69
Pretax Income	3.09	-98.62
Income Tax	-2.12	5.46
Net Income	5.21	-104.08
Free Cash Flow	13.09	-77.83
Gross Margin	62.56%	59.29%
Operating Margin	3.15%	-57.42%
Profit Margin	1.04%	-65.01%
Free Cash Flow Margin	2.60%	-48.62%
Effective Tax Rate	-68.80%	-
EBITDA	15.84	-91.93
EBITDA Margin	3.15%	-57.42%
EBIT	15.84	-91.93
EBIT Margin	3.15%	-57.42%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).